Elevance Health Inc (ELV)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Elevance Health Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 375.80 $ — 67% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 19.5% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 22
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 27.16 | 27.00 – 28.25 | 196,238 | -10.3% | 20 |
| 12/31/2027 | 29.63 | 29.06 – 31.00 | 200,389 | 9.1% | 21 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 4.66 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.81 | -50.20 | 45,442 | 6.60 | 0.90 | 706 | 384 |
| 2025: Q1 | 9.61 | 0.20 | 48,891 | 14.80 | 4.50 | 1,017 | 821 |
| 2025: Q2 | 7.72 | -21.70 | 49,776 | 14.00 | 3.50 | 2,054 | 1,787 |
| 2025: Q3 | 5.27 | 20.80 | 50,711 | 12.30 | 2.30 | 1,135 | 775 |
| 2025: Q4 | 2.47 | 36.30 | 49,747 | 9.50 | 1.10 | 84 | -209 |
| 2026: Q1 | 8.00 | -16.70 | 50,181 | 2.60 | 3.50 | 4,332 | 4,097 |
| 2026: Q2 | 6.71 | -13.10 | 50,474 | 1.40 | 2.90 | 1,913 | 1,626 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 84,978 | 5,419 | 2,470 | 9.21 | 3,205 | 25,100 | 66,387 |
| 2017 | 90,039 | 4,985 | 3,843 | 14.35 | 4,185 | 26,503 | 71,460 |
| 2018 | 92,105 | 5,837 | 3,750 | 14.75 | 3,827 | 28,541 | 72,470 |
| 2019 | 104,213 | 6,733 | 4,807 | 18.47 | 6,061 | 31,728 | 78,254 |
| 2020 | 121,867 | 7,711 | 4,572 | 17.98 | 10,688 | 33,199 | 88,276 |
| 2021 | 138,639 | 8,946 | 6,104 | 24.73 | 8,364 | 36,060 | 97,460 |
| 2022 | 156,595 | 8,451 | 5,894 | 24.28 | 8,399 | 36,243 | 102,755 |
| 2023 | 171,340 | 8,745 | 5,987 | 25.22 | 8,061 | 39,306 | 108,928 |
| 2024 | 176,810 | 8,888 | 5,980 | 25.68 | 5,808 | 41,315 | 116,889 |
| 2025 | 199,125 | 8,112 | 5,662 | 25.53 | 4,290 | 43,882 | 121,494 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Elevance Health, Inc. ist mit ihren Tochtergesellschaften ein Krankenversicherungsunternehmen in den USA.
| Employees | 96,129 |
|---|---|
| Headquarters | Indianapolis, IN |
| Address | 220 Virginia Avenue, 46204 Indianapolis, United States |
| Phone | 833 401 1577 |
| Website | elevancehealth.com |
| IPO Date | 2. Jan 2001 |
| ISIN | US0367521038 |
| Stock Split | 2:1 on 06/01/2005 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Gail Koziara Boudreaux | President, CEO & Director | 1961 |
| Mark Bradley Kaye | Executive VP & CFO | 1980 |
| Peter David Haytaian Esq. | Special Advisor | 1970 |
| Charles Morgan Kendrick Jr. | EVP and President of Commercial & Specialty Health Benefits | 1966 |
| Felicia Farr Norwood | Executive VP & Chief Health Benefits Officer | 1960 |
| Scott Wayne Anglin | SVP, Treasurer & Chief Investment Officer | – |
| Ronald William Penczek | Senior VP, Controller & Chief Accounting Officer | 1965 |
| Nathan Allen Rich | Vice President of Investor Relations | – |
| Erin M. Wessling | Executive VP & Chief Legal Officer | 1978 |
| Julie Goon | Senior Vice President of Public Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 17. Jul 2026 | Boudreaux Gail | President and CEO | Buy | 2,045 | 368.25 | 753,071 |
| 17. Jul 2026 | Boudreaux Gail | President and CEO | Buy | 680 | 366.41 | 249,159 |
| 17. Jul 2026 | Peru Ramiro G | Director | Buy | 1,000 | 366.05 | 366,050 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.